华东医药：DR10624注射液药品临床试验申请已获FDA批准

Core Viewpoint - The company has received FDA approval for a clinical trial of its drug DR10624, aimed at treating metabolic-associated fatty liver disease [1] Group 1 - The company's subsidiary, Zhejiang Daor Biotechnology Co., Ltd., is responsible for the drug application [1] - The FDA notification indicates that the clinical trial can now proceed in the United States [1] - The approved indication for the drug is metabolic-associated fatty liver disease [1]